Common adverse effects include gastrointestinal symptoms, particularly nausea (30-50% of patients), vomiting, diarrhea, and constipation
The body conserves energy by reducing fidgeting, spontaneous movement, and activity intensity
Beginning July 1, 2026, the Medicare GLP-1 Bridge will cover select medications including Foundayo, Wegovy and Zepbound KwikPen for eligible Part D participants
The retatrutide injection site guide includes visual diagrams showing optimal rotation patterns
Postbiotics in functional foods: microbial derivatives shaping health, immunity and next-generation nutrition
1 Type 2 diabetes from insulin resistance accounts for 90% of diabetes cases